FINRA Launches Review of Higher-Risk Structured Products

The Financial Industry Regulatory Authority (FINRA) has announced a targeted review focused on firm supervision and sales practices involving certain higher-risk structured products, specifically non-principal protected “worst-of” structured notes.

According to FINRA, the review is being conducted as part of its broader investor protection mission and will focus on how firms supervise concentrations in these products, particularly in connection with obligations under Regulation Best Interest (Reg BI) and other FINRA rules.

Read the Official FINRA notice:
FINRA Sweep Letter on Non-Principal Protected Worst-Of Structured Notes

What Are “Worst-Of” Structured Notes?

“Worst-of” structured notes are complex investment products whose performance is tied to the lowest-performing underlying asset within a group of referenced securities or indexes.

In non-principal protected structures:

• Investors can lose a substantial portion, or all, of their principal
• Product performance depends on the weakest-performing underlying reference asset
• Risks may be amplified in volatile market conditions

Because of their complexity and risk profile, these products often require heightened supervision, suitability analysis, and investor disclosure considerations.

What FINRA’s Review Will Focus On

FINRA stated that the review will examine how firms:

• Supervise customer concentrations in these products
• Evaluate recommendations under Regulation Best Interest
• Apply supervisory systems and controls
• Monitor registered representative activity involving structured notes

The review will specifically assess whether firms are appropriately identifying and managing situations where investors may hold concentrated positions in higher-risk structured products.

Although the review only directly impacts a subset of firms, FINRA encouraged all firms recommending these products to evaluate their current practices.

Firms may want to review these areas within broader FINRA compliance programs and supervisory frameworks.

Regulation Best Interest and Structured Products

FINRA’s announcement reinforces the growing regulatory focus on how firms apply Reg BI in practice, particularly for complex or higher-risk products.

When recommending structured notes, firms are expected to:

• Understand product risks and features
• Evaluate investor objectives and risk tolerance
• Consider concentration risks
• Maintain strong documentation and supervisory oversight

FINRA has increasingly emphasized that compliance cannot rely solely on disclosures. Firms must demonstrate meaningful supervisory processes and controls.

These expectations often intersect with broader compliance expertise and supervisory consulting.

Why Concentration Risk Matters

Concentration risk occurs when a customer’s portfolio becomes overly exposed to a specific product, issuer, or strategy.

With higher-risk structured notes, concentration concerns may arise when:

• Investors allocate significant portions of assets to a single product category
• Risk exposure is not fully understood
• Market volatility increases downside potential

FINRA’s review suggests firms should ensure concentration monitoring systems are functioning effectively and supported by clear supervisory procedures.

What Firms Should Consider Reviewing Now

Even firms not directly contacted by FINRA may benefit from proactively evaluating their practices.

Areas to review may include:

• Supervisory procedures related to structured products
• Reg BI documentation and recommendation processes
• Concentration thresholds and escalation procedures
• Training for registered representatives
• Communications and disclosures provided to customers

Firms preparing for future reviews may also incorporate these areas into broader
regulatory exam preparation.

Increasing Regulatory Focus on Complex Products

FINRA’s review reflects a broader regulatory trend toward increased scrutiny of:

• Complex investment products
• High-risk recommendations
• Product concentration supervision
• Documentation and oversight controls

As regulators continue focusing on how firms supervise these areas, firms should ensure compliance programs are operationally effective, not simply policy-based.

Key Takeaways

• FINRA is reviewing firm supervision of non-principal protected “worst-of” structured notes
• The focus includes concentration risk and compliance with Regulation Best Interest
• Firms recommending these products should proactively evaluate supervisory systems and controls
• Strong documentation, oversight, and monitoring remain essential regulatory priorities

Contact Us

Have questions about structured product supervision or Regulation Best Interest compliance?

Contact Quadrant Regulatory Group to discuss your firm’s supervisory controls, risk management practices, and regulatory readiness.